{ }
Catherine Wood, founder of ARK Investment Management, acquired 1,623,868 shares of CRISPR Therapeutics AG at $51.17 each, raising her firm's total holdings to 9,122,493 shares, or 4.24% of the portfolio. This move underscores her confidence in the biotechnology sector and CRISPR's gene-editing technologies, despite the company's current overvaluation. CRISPR Therapeutics, valued at $4.19 billion, is a leader in gene editing, with a focus on addressing significant medical needs through innovative therapeutics.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.